Automation, digital twins, and artificial intelligence (AI)-based process optimization enables greater flexibility in biopharma manufacturing, lower risk of contamination, and potentially faster delivery of both small molecule and biologics drugs.
Growing demand for the development and production of complex drugs, including antibody-drug conjugates, biologics, cell and gene therapies, and mRNA-based medications, are leading to the adoption of smart manufacturing platforms and analytics.
This eHandbook examines the latest smart pharma and automation trends in the biopharma industry, as manufacturers look to eliminate human errors and optimize processes while making production faster, more reliable, and easier to manage.
